Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review.

ABSTRACT:

Introduction

A growing amount of evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) may independently increase the risk of coronary artery disease and acute coronary syndrome, thus necessitating revascularization interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) [2,3]. However, a limited number of studies have evaluated the impact of MASLD on the outcomes of these interventions.

Methods

A comprehensive search of the PubMed/MEDLINE and Embase databases was conducted to identify relevant studies from August 2015 to August 2025 using a combination of Medical Subject Headings (MeSH) terms and text words related to MASLD and cardiovascular revascularization.

Results

Two hundred nin

SUBMITTER: Gries JJ 

PROVIDER: S-EPMC12417393 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature